Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra for Pyrexia Management in BRAF+ Melanoma Patients
NCT04652258Phase 2Terminated
- Sponsor
- University of Zurich
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in fever, sponsored by University of Zurich. Started Feb 2021; status: terminated.
02
Drugs
tocilizumab
03
Conditions
fever
Beyond the preview
Go deeper on NCT04652258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652258.